Effect of Concomitant Administration of Trospium Chloride Extended Release on the Steady-state Pharmacokinetics of Metformin in Healthy Adults

Overview

Journal Clin Drug Investig

Date 2013 Jan 18

PMID 23325481

Citations 6

Authors

Michael G Oefelein

Warren Tong

Sam Kerr

Kavitha Bhasi

Rina K Patel

Dale Yu

Affiliations

Soon will be listed here.

Abstract

Background: Overactive bladder (OAB) is often associated with a number of co-morbid medical conditions, including diabetes mellitus. This may necessitate several concomitant treatments, thus creating the potential for drug-drug interactions (DDIs). Trospium is renally eliminated, not metabolized via cytochrome P450; therefore, cytochrome P450 DDIs are unlikely. However, coadministration with another renally eliminated drug (e.g., metformin) may theoretically result in a DDI.

Objective: The objective of this study was to evaluate the pharmacokinetics (plasma and urine) and safety/tolerability of the coadministration of trospium chloride extended release (XR) and metformin under steady-state conditions in healthy male and female subjects.

Methods: In a single-centre, randomized, open-label, two-group, two-period study in healthy males and females aged 18-45 years, 44 subjects received oral metformin 500 mg twice daily for 3.5 days during one period, and oral trospium chloride XR 60 mg once daily for 10 days, followed by trospium chloride XR 60 mg once daily for 4 days plus metformin 500 mg twice daily for 3.5 days during the other period. The two periods occurred in a crossover fashion, separated by a 3-day washout period.

Results: Trospium chloride XR coadministration did not alter metformin steady-state pharmacokinetics. Metformin coadministration reduced trospium steady-state maximum plasma concentration (by 34 %) and area under the concentration-time curve from 0-24 hours (by 29 %). Neither drug's renal clearance was affected. No safety/tolerability issues of concern were observed with coadministration.

Conclusion: No dosage adjustment is necessary for metformin when coadministered with trospium chloride XR.

Citing Articles

The development and benefits of metformin in various diseases.

Dong Y, Qi Y, Jiang H, Mi T, Zhang Y, Peng C Front Med. 2023; 17(3):388-431.

PMID: 37402952 DOI: 10.1007/s11684-023-0998-6.

Organic Cation Transporter 1 an Intestinal Uptake Transporter: Fact or Fiction?.

Wenzel C, Drozdzik M, Oswald S Front Pharmacol. 2021; 12:648388.

PMID: 33935750 PMC: 8080103. DOI: 10.3389/fphar.2021.648388.

Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms.

Abdelhamid M, Zayed A, Ghoneima W, Elmarakbi A, El Sheemy M, Aref A World J Urol. 2017; 35(8):1261-1268.

PMID: 28050642 DOI: 10.1007/s00345-016-1988-y.

Limited sampling strategy for determining metformin area under the plasma concentration-time curve.

Santoro A, Stage T, Struchiner C, Christensen M, Brosen K, Suarez-Kurtz G Br J Clin Pharmacol. 2016; 82(4):1002-10.

PMID: 27324407 PMC: 5137825. DOI: 10.1111/bcp.13049.

Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates.

Hacker K, Maas R, Kornhuber J, Fromm M, Zolk O PLoS One. 2015; 10(9):e0136451.

PMID: 26327616 PMC: 4556614. DOI: 10.1371/journal.pone.0136451.

References

Sandage B, Sabounjian L, Shipley J, Profy A, Lasseter K, Fox L . Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. J Clin Pharmacol. 2006; 46(7):776-84. DOI: 10.1177/0091270006289481. View

Lawrence J, Lukacz E, Liu I, Nager C, Luber K . Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study. Diabetes Care. 2007; 30(10):2536-41. DOI: 10.2337/dc07-0262. View

Chancellor M, Oefelein M, Vasavada S . Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourol Urodyn. 2009; 29(4):551-4. DOI: 10.1002/nau.20787. View

Garber A, Handelsman Y, Einhorn D, Bergman D, Bloomgarden Z, Fonseca V . Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008; 14(7):933-46. DOI: 10.4158/EP.14.7.933. View

Lee A, Morley J . Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998; 6(1):47-53. DOI: 10.1002/j.1550-8528.1998.tb00314.x. View

Ogden C, Carroll M, Curtin L, McDowell M, Tabak C, Flegal K . Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006; 295(13):1549-55. DOI: 10.1001/jama.295.13.1549. View

Dallosso H, McGrother C, Matthews R, Donaldson M . The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int. 2003; 92(1):69-77. DOI: 10.1046/j.1464-410x.2003.04271.x. View

Silver N, Sandage B, Sabounjian L, Schwiderski U, Shipley J, Harnett M . Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. J Clin Pharmacol. 2009; 50(2):143-50. DOI: 10.1177/0091270009345498. View

Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N . Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab. 2002; 4(1):49-55. DOI: 10.1046/j.1463-1326.2002.00181.x. View

10.

Srinivasan S, Ambler G, Baur L, Garnett S, Tepsa M, Yap F . Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006; 91(6):2074-80. DOI: 10.1210/jc.2006-0241. View

11.

Fusgen I, Hauri D . Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther. 2000; 38(5):223-34. DOI: 10.5414/cpp38223. View

12.

Lalic N, Paulweber M, Stadlmayr A, Kedenko L, Djordevic P, Abraham C . A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010; 42 Suppl 1:S3-36. DOI: 10.1055/s-0029-1240928. View

13.

Stewart W, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R . Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20(6):327-36. DOI: 10.1007/s00345-002-0301-4. View

14.

Wenge B, Geyer J, Bonisch H . Oxybutynin and trospium are substrates of the human organic cation transporters. Naunyn Schmiedebergs Arch Pharmacol. 2011; 383(2):203-8. DOI: 10.1007/s00210-010-0590-x. View

15.

Onukwugha E, Zuckerman I, McNally D, Coyne K, Vats V, Daniel Mullins C . The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care. 2009; 15(4 Suppl):S90-7. View

16.

Teleman P, Lidfeldt J, Nerbrand C, Samsioe G, Mattiasson A . Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women. BJOG. 2004; 111(6):600-4. DOI: 10.1111/j.1471-0528.2004.00137.x. View

17.

Berghofer A, Pischon T, Reinhold T, Apovian C, Sharma A, Willich S . Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008; 8:200. PMC: 2441615. DOI: 10.1186/1471-2458-8-200. View

18.

Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View

19.

Zhou M, Xia L, Wang J . Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007; 35(10):1956-62. PMC: 2672958. DOI: 10.1124/dmd.107.015495. View

20.

Glueck C, Fontaine R, Wang P, Subbiah M, Weber K, Illig E . Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001; 50(7):856-61. DOI: 10.1053/meta.2001.24192. View